Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lens crystallin proteins are the primary structural components of the ocular lens, essential for maintaining its transparency and high refractive index (Hoenders & Bloemendal, 1983). These proteins, categorized into alpha, beta, and gamma families, are characterized by their extreme longevity and lack of turnover, making them highly susceptible to cumulative post-translational modifications over a lifetime (Balfour & Clissold, 1990). The sulfhydryl (-SH) groups of cysteine residues within these proteins are particularly vulnerable to oxidative stress, which increases as levels of the endogenous antioxidant glutathione decline with age (Babizhayev et al., 2001). Oxidation of these groups leads to the formation of inter- and intra-molecular disulfide bonds, resulting in protein cross-linking, aggregation, and the formation of light-scattering opacities known as cataracts (Truscott, 2005). Therapeutic strategies targeting these sulfhydryl groups aim to prevent or reverse this oxidative damage, either by acting as sacrificial antioxidants, stabilizing the protein structure, or reducing existing disulfide bridges to restore protein solubility (Balfour & Clissold, 1990). While pharmacological intervention remains a challenge due to the dense, avascular structure of the lens, these proteins represent a critical target for non-surgical cataract management and the preservation of visual acuity.
Prevention of oxidative modification and cross-linking of crystallin proteins by protecting or regenerating sulfhydryl groups, thereby maintaining protein solubility and lens transparency (Balfour & Clissold, 1990; Babizhayev et al., 2001).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lens crystallin protein.